Expression order of alpha-v and beta-3 integrin subunits in the N-methyl-N-nitrosourea-induced rat mammary tumor model

Cancer Investigation

Volumn 27, Issue 5, 2009, Pages 496-503

  Rezaeipoor, Robabeh ^a   Chaney, Eric J ^a   Oldenburg, Amy L ^a   Boppart, Stephen A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Alpha v beta 3 subunits; Breast cancer; Expression; Integrin; Mammary tumors; Molecular imaging

Indexed keywords

BETA3 INTEGRIN; CD51 ANTIGEN; METHYLNITROSOUREA; MONOCLONAL ANTIBODY; ALKYLATING AGENT; PROTEIN SUBUNIT; VITRONECTIN RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE SECTION; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; ENZYME IMMUNOASSAY; EXPERIMENTAL NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WISTAR RAT;

ADENOCARCINOMA; ALKYLATING AGENTS; ANIMALS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; PROTEIN SUBUNITS; RATS; RATS, WISTAR; UMBILICAL VEINS;

EID: 67449088597     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802620836     Document Type: Article

References (43)

1. Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110, 673-687.
2. Allen, C.M.; Sharman, W.M.; Madeleine, C.L.; Van Lier, J.E.; Weber, J.M. Attenuation of photodynamically induced apoptosis by an RGD containing peptide, Photochem Photobiol Sci 2002, 1, 246-254.
3. Ruoslahti, E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999, 76, 1-20.
4. Eliceiri, B.P.; Cheresh, D.A. The role of alpha v beta 3 integrins during angiogenesis. J Clin Invest 1999, 103, 1227-1230.
5. 3-mediated adhesion to fibronectin vs vitronectin. J Biol Chem 2001, 276(34), 31684-31690.
6. v-associated integrin β subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J M Histol 2005, 36(1-2), 119-129.
7. Sigstad, E.; Dong, H.P.; Nielson, S.; Berner, A.; Davidson, B.; Rinsberg, B. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. Diagn Cytopathol 2004, 33(5), 325-331.
8. Gui, G.P.; Wells, C.A.; Yeomans, P.; Jordan, S.E.; Vinson, G.P.; Carpenter, R. Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis. Surg Oncol 1996, 22(3), 254-258. (Pubitemid 26229675)
9. Edlund, M.; Miyamoto, T.; Sikes, R.A.; Ogle, R.; et al. Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 2001, 12(2), 99-107. (Pubitemid 32194899)
10. Boppart, S.A.; Oldenburg, A.L.; Xu, C.; Marks, D.L. Optical probes and techniques for molecular contrast enhancement in coherence imaging. J Biomed Opt 2005, 10(4), 0412081-04120814.
11. Oldenburg, A.L.; Toublan, F.J.J.; Suslick, K.S.; Wei, A.; Boppart, S.A. Magnetomotive contrast for in vivooptical coherence tomography. Opt Expr 2005, 13(17), 6597-6614. (Pubitemid 41230884)
12. Tobulan, F.J.J.; Boppart, S.A.; Suslick, K.S. Tumor targeting by surface-modified protein microspheres. J Am Chem Soc 2006, 128, 3472-3473.
13. Zysk, A.M.; Nguyen, F.T.; Oldenburg, A.L.; Marks, D.L.; Boppart, S.A. Optical coherence tomography: a review of clinical application development from bench to bedside. J Biomed Opt 2007, 12, 051403.
14. Artemov, D.; Mori, N.; Okollie, B.; Bhujwalla, Z.M. MR molecular imaging of the her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003, 49, 403-408.
15. Funovics, M.A.; Kapeller, B.; Hoeller, C.; Su, H.; Kunstfeld, R.; Puig, S.; Macfelda, K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imag 2004, 22, 0843-0850. (Pubitemid 38962321)
16. Aaron, J.S.; Oh, J.; Larson, T.A.; Kumar, S.; Milner, T.E.; Sokolov, K.V. Increased optical contrast in imaging of epidermal growth factor receptor using magnetically actuated hybrid gold/iron oxide nanoparticles. Opt Expr 2006, 14(29), 12930-12943.
17. Gruttner, C.; Muller, K.; Teller, J.; Westphal, F.; Foreman, A.; Ivkov, R. Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. J Magn Magn Mater 2007, 311, 181-186.
18. Lee, T.M.; Oldenburg, A.L.; Sitafalwalla, S.; Mark, D.L.; Luo, W.; Toublan, F.J.J.; Suslick, K.S.; Boppart, S.A. Engineered microsphere contrast agent for optical coherence tomography. Opt Lett 2003, 28(17), 1546-1548.
19. Oldenburg, A.L.; Crecea, V.; Rinne, S.A.; Boppart, S.A. Phase-resolved magnetomotive OCT for imaging nanomolar concentrations of magnetic nanoparticles in tissues. Opt Expr 2008, 16(15), 11525-11539.
20. Magnetomotive contrast for in vivo optical coherence tomography. Opt Expr 2005, 13(17), 6597-6614. (Pubitemid 41230884)
21. Frangioni, J.V. Translating in vivo diagnostics into clinical reality. Nat Biotechnol 2006, 24, 909-913.
22. Li, C.; Wang, W.; Wu, Q.; Ke, S.; Houston, J.; Sevick-Muraca, E.; Dong, L.; Chow, D.; Charnsangavej, C.; Gelovani, J.G. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol 2006, 33, 349-358.
23. Adams, K.E.; Ke, S.; Kwon, S.; Liang, F.; Fan, Z.; Lu, Y. Comparison of visible and nearinfrared wavelength excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 2007, 12, 024017. (Pubitemid 46930498)
24. Van Belle, P.A.; Elennitsas, R.; Satyamoorthy, K.; et al. Progression related expression of beta3 integrin in melanomas. Hum Pathol 1999, 30, 562-567.
25. Switala-Jelen, K.; Dabrowska, K.; Opolski, A.; Lipinska, L.; Nowaczyk, M.; Gorski, A. The biological functions of beta3 integrins. Folia Biol (Paraha) 2004, 50, 143-152.
26. Trikha, M.; Timar, J.; Zacharek, A.; Nemeth, J.A.; Cai, Y.L.; Done, B.; Somlai, B.; Raso. E.; Ladanyi, A.; Honn, K.V. Role for beta3 integrins in human melanoma growth and survival. Int J Cancer 2002, 101, 156-167.
27. Wang, X.; Ferreira, A.M.; Shao, Q.; Laird, D.W.; Sandig, M. Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 2005, 63, 65-80. (Pubitemid 40365391)
28. Gruber, G.; Hess, J.; Stiefel, C.; Aebersold, D.M.; Zimmer, Y.; Greiner, R.H.; Studer, U.; Altermatt, H.J.; Hlushchuk, R.; Djonov, V. Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br J Cancer 2005, 92, 41-46. (Pubitemid 40188434)
29. Pignatelli, M.; Cardillo, M.R.; Hanby, A.; Stamp, G. Integrins and their accessory adhesion molecules in mammary carcinomas. Hum Pathol 1992, 23, 1159-1166.
30. Kawahara, E.; Ooi, A.; Nakanishi, I. Integrin distribution in gastric carcinoma: association of beta3 and beta5 integrins with tumor invasiveness. Pathol Int 1995, 45, 493-500.
31. Albeda, S.M.; Mette, S.A.; Elder, D.E.; Stewart, R.; Damjanovich, L.; Herlyn, M.; Buck, C.A. Integrin distribution in malignant-melanoma: association of the beta3 subunit with tumor progression. Cancer Res 1990, 50, 6757-6764.
32. Gingras, M.C.; Roussel, E.; Bruner, J.M.; Branch, C.D.; Moser, R.P. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1995, 57, 143-153.
33. Bloch, S.; Xu, B.; Ye, Y.; et al. Targeting beta-3 integrin using a linear hexapeptide labeled with a near-infrared fluorescent molecular probe. Mol Pharm 2006, 3(5), 539-549.
34. v subunit expressed on cultured monocytes (macrophages). J Biol Chem 1990, 265, 823-830.
35. Cheresh, D.A.; Smith, J.; Cooper, H.; Quaranta, V. A novel vitronectin receptor integrin is responsible for distinct adhesive properties of carcinoma cells. Cell 1989, 57, 59-69. (Pubitemid 19098868)
36. 3. J Biol Chem 1997, 269(6), 4641-4647.
37. Felding-Habermann, B.; Mueller, B.M.; Romerdahl, C.A.; Cheresh, D.A. Involvement of integrin alpha v gene expression in human melanoma tumorigenicity. J Clin Invest 1992, 89(6), 2018-2022.
38. Albelda, S.M.; Mette, S.A.; Elder, D.E; Stewart, R.M; Damjanovich, L.; Herlyn, M.; Clayton, A. Integrin distribution in malignant melanoma. Cancer Res 1990, 50, 6757-6764.
39. Blystone, S.D.; Slater, S.E.; Williams, M.P.; Crow, M.T.; Brown, E.J. A molecular mechanism of integrin crosstalk. J Cell Biol 1999, 145, 889-897.
40. Schwartz, M.A.; Ginsberg, M.H. Networks and crosstalk: integrin signalling spreads. Nat Cell Biol 2002, 4, E65-E68.
41. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79(7), 1157-1164.
42. Brooks, P.C.; Strömblad, S.; Klemke, R.; Visscher, D.; Sarkar, F.H.; Cheresh, D.A. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96(4), 1815-1822.
43. Friedlander, M.; Brooks, P.C.; Shaffer, R.W.; Kincaid, C.M.; Varner, J.A.; Cheresh, D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270(5241), 1500-1502.